Assessing the Real-World Effectiveness of Immunizations for Respiratory Syncytial Virus

Assessing the Real-World Effectiveness of Immunizations for Respiratory Syncytial Virus

This Viewpoint discusses recommendations from the US Centers for Disease Control and Prevention for newly licensed immunizations for respiratory syncytial virus in infants, children with high-risk conditions, and older adults.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA : the journal of the American Medical Association 2024-06, Vol.331 (21), p.1799-1800
Hauptverfasser: Dawood, Fatimah S, Payne, Amanda B, McMorrow, Meredith L
Format: Artikel
Sprache:eng
Schlagworte:
Adults
Children
Effectiveness
Fatalities
Hospitalization
Illnesses
Immunization
Infants
Monoclonal antibodies
Older people
Populations
Prevention
Public health
Respiratory diseases
Respiratory syncytial virus
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1800
container_issue 21
container_start_page 1799
container_title JAMA : the journal of the American Medical Association
container_volume 331
creator Dawood, Fatimah S
Payne, Amanda B
McMorrow, Meredith L
description This Viewpoint discusses recommendations from the US Centers for Disease Control and Prevention for newly licensed immunizations for respiratory syncytial virus in infants, children with high-risk conditions, and older adults.
doi_str_mv 10.1001/jama.2024.5859
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3037395400</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>2817460</ama_id><sourcerecordid>3069264685</sourcerecordid><originalsourceid>FETCH-LOGICAL-a297t-c1abcbd782afb48bea37429e2f84a09fdb1209dafa37a070c8686666d6fc08d23</originalsourceid><addsrcrecordid>eNpdkMtLxDAQh4Mo7vq4evAgBS9euk4eTZOjyPoAQfC1x5K2iWZpmzVphfWvN2VXD85lYH7fDMOH0AmGGQbAl0vVqhkBwmaZyOQOmuKMipRmUuyiKYAUac4Em6CDEJYQC9N8H02o4EC4yKZocRWCDsF270n_oZMnrZp04XxTJ3NjdNXbL93FPHEmuW_bobPfqreuC4lxPtJhZb3qnV8nz-uuWvdWNcmb9UM4QntGNUEfb_sher2Zv1zfpQ-Pt_fXVw-pIjLv0wqrsirrXBBlSiZKrWjOiNTECKZAmrrEBGStTJwryKESXPBYNTcViJrQQ3Sxubvy7nPQoS9aGyrdNKrTbggFBZpTmTGAiJ7_Q5du8F38LlJcEs6ikUjNNlTlXQhem2Llbav8usBQjMqLUXkxKi9G5XHhbHt2KFtd_-G_jiNwugHGvd-UCJwzDvQHRNOF8Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3069264685</pqid></control><display><type>article</type><title>Assessing the Real-World Effectiveness of Immunizations for Respiratory Syncytial Virus</title><source>American Medical Association Journals</source><creator>Dawood, Fatimah S ; Payne, Amanda B ; McMorrow, Meredith L</creator><creatorcontrib>Dawood, Fatimah S ; Payne, Amanda B ; McMorrow, Meredith L</creatorcontrib><description>This Viewpoint discusses recommendations from the US Centers for Disease Control and Prevention for newly licensed immunizations for respiratory syncytial virus in infants, children with high-risk conditions, and older adults.</description><identifier>ISSN: 0098-7484</identifier><identifier>ISSN: 1538-3598</identifier><identifier>EISSN: 1538-3598</identifier><identifier>DOI: 10.1001/jama.2024.5859</identifier><identifier>PMID: 38602685</identifier><language>eng</language><publisher>United States: American Medical Association</publisher><subject>Adults ; Children ; Effectiveness ; Fatalities ; Hospitalization ; Illnesses ; Immunization ; Infants ; Monoclonal antibodies ; Older people ; Populations ; Prevention ; Public health ; Respiratory diseases ; Respiratory syncytial virus</subject><ispartof>JAMA : the journal of the American Medical Association, 2024-06, Vol.331 (21), p.1799-1800</ispartof><rights>Copyright American Medical Association Jun 4, 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-a297t-c1abcbd782afb48bea37429e2f84a09fdb1209dafa37a070c8686666d6fc08d23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jamanetwork.com/journals/jama/articlepdf/10.1001/jama.2024.5859$$EPDF$$P50$$Gama$$H</linktopdf><linktohtml>$$Uhttps://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.5859$$EHTML$$P50$$Gama$$H</linktohtml><link.rule.ids>64,314,776,780,3327,27901,27902,76232,76235</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38602685$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dawood, Fatimah S</creatorcontrib><creatorcontrib>Payne, Amanda B</creatorcontrib><creatorcontrib>McMorrow, Meredith L</creatorcontrib><title>Assessing the Real-World Effectiveness of Immunizations for Respiratory Syncytial Virus</title><title>JAMA : the journal of the American Medical Association</title><addtitle>JAMA</addtitle><description>This Viewpoint discusses recommendations from the US Centers for Disease Control and Prevention for newly licensed immunizations for respiratory syncytial virus in infants, children with high-risk conditions, and older adults.</description><subject>Adults</subject><subject>Children</subject><subject>Effectiveness</subject><subject>Fatalities</subject><subject>Hospitalization</subject><subject>Illnesses</subject><subject>Immunization</subject><subject>Infants</subject><subject>Monoclonal antibodies</subject><subject>Older people</subject><subject>Populations</subject><subject>Prevention</subject><subject>Public health</subject><subject>Respiratory diseases</subject><subject>Respiratory syncytial virus</subject><issn>0098-7484</issn><issn>1538-3598</issn><issn>1538-3598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpdkMtLxDAQh4Mo7vq4evAgBS9euk4eTZOjyPoAQfC1x5K2iWZpmzVphfWvN2VXD85lYH7fDMOH0AmGGQbAl0vVqhkBwmaZyOQOmuKMipRmUuyiKYAUac4Em6CDEJYQC9N8H02o4EC4yKZocRWCDsF270n_oZMnrZp04XxTJ3NjdNXbL93FPHEmuW_bobPfqreuC4lxPtJhZb3qnV8nz-uuWvdWNcmb9UM4QntGNUEfb_sher2Zv1zfpQ-Pt_fXVw-pIjLv0wqrsirrXBBlSiZKrWjOiNTECKZAmrrEBGStTJwryKESXPBYNTcViJrQQ3Sxubvy7nPQoS9aGyrdNKrTbggFBZpTmTGAiJ7_Q5du8F38LlJcEs6ikUjNNlTlXQhem2Llbav8usBQjMqLUXkxKi9G5XHhbHt2KFtd_-G_jiNwugHGvd-UCJwzDvQHRNOF8Q</recordid><startdate>20240604</startdate><enddate>20240604</enddate><creator>Dawood, Fatimah S</creator><creator>Payne, Amanda B</creator><creator>McMorrow, Meredith L</creator><general>American Medical Association</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7TK</scope><scope>7TS</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20240604</creationdate><title>Assessing the Real-World Effectiveness of Immunizations for Respiratory Syncytial Virus</title><author>Dawood, Fatimah S ; Payne, Amanda B ; McMorrow, Meredith L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a297t-c1abcbd782afb48bea37429e2f84a09fdb1209dafa37a070c8686666d6fc08d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adults</topic><topic>Children</topic><topic>Effectiveness</topic><topic>Fatalities</topic><topic>Hospitalization</topic><topic>Illnesses</topic><topic>Immunization</topic><topic>Infants</topic><topic>Monoclonal antibodies</topic><topic>Older people</topic><topic>Populations</topic><topic>Prevention</topic><topic>Public health</topic><topic>Respiratory diseases</topic><topic>Respiratory syncytial virus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dawood, Fatimah S</creatorcontrib><creatorcontrib>Payne, Amanda B</creatorcontrib><creatorcontrib>McMorrow, Meredith L</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>JAMA : the journal of the American Medical Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dawood, Fatimah S</au><au>Payne, Amanda B</au><au>McMorrow, Meredith L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessing the Real-World Effectiveness of Immunizations for Respiratory Syncytial Virus</atitle><jtitle>JAMA : the journal of the American Medical Association</jtitle><addtitle>JAMA</addtitle><date>2024-06-04</date><risdate>2024</risdate><volume>331</volume><issue>21</issue><spage>1799</spage><epage>1800</epage><pages>1799-1800</pages><issn>0098-7484</issn><issn>1538-3598</issn><eissn>1538-3598</eissn><abstract>This Viewpoint discusses recommendations from the US Centers for Disease Control and Prevention for newly licensed immunizations for respiratory syncytial virus in infants, children with high-risk conditions, and older adults.</abstract><cop>United States</cop><pub>American Medical Association</pub><pmid>38602685</pmid><doi>10.1001/jama.2024.5859</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0098-7484
ispartof JAMA : the journal of the American Medical Association, 2024-06, Vol.331 (21), p.1799-1800
issn 0098-7484
1538-3598
1538-3598
language eng
recordid cdi_proquest_miscellaneous_3037395400
source American Medical Association Journals
subjects Adults
Children
Effectiveness
Fatalities
Hospitalization
Illnesses
Immunization
Infants
Monoclonal antibodies
Older people
Populations
Prevention
Public health
Respiratory diseases
Respiratory syncytial virus
title Assessing the Real-World Effectiveness of Immunizations for Respiratory Syncytial Virus
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T12%3A09%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessing%20the%20Real-World%20Effectiveness%20of%20Immunizations%20for%20Respiratory%20Syncytial%20Virus&rft.jtitle=JAMA%20:%20the%20journal%20of%20the%20American%20Medical%20Association&rft.au=Dawood,%20Fatimah%20S&rft.date=2024-06-04&rft.volume=331&rft.issue=21&rft.spage=1799&rft.epage=1800&rft.pages=1799-1800&rft.issn=0098-7484&rft.eissn=1538-3598&rft_id=info:doi/10.1001/jama.2024.5859&rft_dat=%3Cproquest_cross%3E3069264685%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3069264685&rft_id=info:pmid/38602685&rft_ama_id=2817460&rfr_iscdi=true